Wall Street Analysts Update Ratings and Price Targets for Nuvation Bio
Several financial institutions updated their investment ratings and price targets for Nuvation Bio Inc. on November 6, 2026.
Stocks · News reference
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual Meeting
Nuvation Bio announced that it will present updated Phase 2 J201 study results and three posters on ongoing studies of its IDH1 inhibitor, safusidenib, at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
B. Riley and RBC Adjust Nuvation Bio Price Targets
Following the company's third-quarter earnings report, analysts at B. Riley and RBC adjusted their price targets for Nuvation Bio while maintaining positive ratings.
RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $17
Nuvation Bio Inc. Reports Third Quarter 2026 Financial Results
Nuvation Bio Inc. announced its financial results for the third quarter of 2026, reporting revenue of $45.0 million, which exceeded the FactSet consensus estimate of $34.4 million.
Nuvation Bio Q3 EPS $(0.12), Inline, Sales $44.951M Beat $34.224M Estimate
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
Nuvation Bio Inc. is expanding its pivotal Phase 3 SIGMA clinical trial for safusidenib, an investigational therapy for IDH1-mutant glioma, into six European nations.